Abstract

Background Collecting duct renal cell carcinoma (CDRCC) is a rare type of renal cancer characterized by a poor prognosis. The aim of this work was to develop a nomogram predicting the overall survival (OS) and cancer-specific survival (CSS) for patients with CDRCC. Methods A total of 324 eligible patients diagnosed with CDRCC from 2004 to 2015 were identified using the data from the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier curve was used to estimate the 1-, 3-, and 5-year OS and CSS of these patients. Univariate and multivariate Cox regression models were performed to identify the independent risk factors associated with OS and CSS. The nomogram was developed based on these factors and evaluated by the concordance index (C-index) and calibration curves using the bootstrap resample method. The predictive accuracy of the nomogram was also compared with the manual of the American Joint Committee on Cancer (AJCC). Results The estimated 1-, -3, and 5-year OS and CSS rates in the analytic cohorts were 56.4% and 60%, 32.5% and 37.3%, and 28.7% and 33.6%, respectively. The multivariate model revealed that age, tumor size, tumor grade, N stage, M stage, surgical type, and chemotherapy were independent predicted factors for OS, while tumor size, tumor grade, N stage, M stage, surgical type, and chemotherapy were independently linked to CSS. A nomogram was developed using these factors with relatively good discrimination and calibration. The C-index for OS and CSS was 0.764 (95% CI: 0.735~0.793) and 0.783 (95% CI: 0.754~0.812), which was superior to the AJCC stage (C-index: 0.685 (95% CI: 0.654~0.716) and 0.703 (95% CI: 0.672~0.734)). Patients were divided into low-risk, intermediate-risk, and high-risk groups according to the total points calculated by the nomogram. Patients in the low-risk group (97 mo and not reached) experienced significantly long median OS and CSS compared to the intermediate-risk (17 mo and 18 mo) and high-risk groups (5 mo for both). The calibration curves showed a good agreement between the predicted and actual probability related to OS and CSS. Conclusion CDRCC has an aggressively biologic behavior with relatively poor prognosis. A survival prediction nomogram making an individualized evaluation of OS and CSS in patients with CDRCC was presented, potentially helping urologists to make a better risk stratification.

Highlights

  • Renal cell carcinoma (RCC) is one of the most common human malignancies worldwide, and its incidence steadily increased in most countries [1]

  • 36 (11.1%) cases were subjected to radiotherapy and 88 (27.2%) cases were treated with chemotherapy

  • The concordance index (C-index) of the conventional American Joint Committee on Cancer (AJCC) stage was 0.685 and 0.703 in predicting overall survival (OS) and cancer-specific survival (CSS), which was significantly inferior to that of our nomogram

Read more

Summary

Introduction

Renal cell carcinoma (RCC) is one of the most common human malignancies worldwide, and its incidence steadily increased in most countries [1]. The prognosis in patients with RCC is generally favorable, with 5-year overall survival (OS) and cancer-specific (CSS) rates of 73.2%~87.9% and 84%~95%, respectively [2, 3]. The above models were established mainly based on a population of a clear cell subtype It is currently unknown whether it is still accurate enough to predict the prognosis for other subtypes of RCC. The aim of this work was to develop a nomogram predicting the overall survival (OS) and cancer-specific survival (CSS) for patients with CDRCC. The nomogram was developed based on these factors and evaluated by the concordance index (C-index) and calibration curves using the bootstrap resample method. A survival prediction nomogram making an individualized evaluation of OS and CSS in patients with CDRCC was presented, potentially helping urologists to make a better risk stratification

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call